{
  "id": "cluster_9_doc4",
  "content": "Investigational biosimilar SB-341 showed promising Phase 2 results for refractory spondyloarthritis. Study participants at Sunset Hills Regional received biweekly infusions with 73% showing 50% pain reduction. Lead researcher Dr. Elaine Martinson presented findings via PX203 encrypted teleconference on 12/05/2023. Next-phase enrollment requires documented TNF inhibitor failure.",
  "metadata": {
    "format": "research_note"
  }
}